Use of clomipramine as chemotherapy of the chronic phase of Chagas disease

Parasitology

Volumn 140, Issue 7, 2013, Pages 917-927

  Fauro, Romina ^a   Presti, Silvina Lo ^a,b   Bazan, Carolina ^a   Baez, Alejandra ^a   Strauss, Mariana ^a   Triquell, Fernanda ^a   Cremonezzi, David ^a   Negrete, Olga Sanchez ^c   Willhuber, Gaston Camino ^a   Paglini Oliva, Patricia ^a   Rivarola, Hector Walter ^a,d  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^d Universidad Nacional de La Rioja   (Argentina)

Author keywords

cardiac chronic stage; Chagas disease; clomipramine; treatment; trypanothione reductase

Indexed keywords

CLOMIPRAMINE; PROTOZOON ANTIBODY; TRYPANOTHIONE REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HEART MUSCLE; HEART MUSCLE FIBROSIS; MALE; MOUSE; NONHUMAN; PARASITEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKELETAL MUSCLE; SURVIVAL RATE; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

MUS; TRYPANOSOMA CRUZI;

EID: 84877053820     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182013000103     Document Type: Article

References (55)

1. Amaral, L., Viveiros, M. and Kristiansen, J. E. (2001). Phenothiazines: potential alternatives for management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Tropical Medicine and International Health 12, 1016-1022.
2. Barbosa Marcon, G. E., Martins de Albuquerque, D., Martins Batista, A., Durante Andrade, P., Almeida, E. A., Guariento, M. E., Teixeira, M. A. B. and Botelho Costa, S. C. (2011). Trypanosoma cruzi: parasite persistence in tissues in chronic chagasic Brazilian patients. Memórias do Instituto Oswaldo Cruz 106, 85-91.
3. Bazán, C., Lo Presti, M. S., Rivarola, H.W., Triquell, M. F., Fretes, R., Fernández, A. R., Enders, J. and Paglini-Oliva, P. (2008). Chemotherapy of chronic indeterminate Chagas disease 'A novel approach to treatment'. Parasitology Research 103, 663-669.
4. Benoist, C. and Mathis, D. (2001). Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nature Immunology 2, 797-801.
5. Benson, T. J., McKie, J. H., Garforth, J., Borges, A., Fairlamb, A. H. and Douglas, K. T. (1992). Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Biochemical Journal 286, 9-11.
6. Bonney, K.M. and Engman, D. M. (2008). Chagas heart disease pathogenesis: one mechanism or many? Current Molecular Medicine 8, 510-518.
7. Bustamante, J. M., Rivarola, H.W., Fernandez, A. R., Enders, J. E., Fretes, R., Palma, J. A. and Paglini-Oliva, P. A. (2003). Indeterminate Chagas disease: Trypanosoma cruzi strain and reinfections are factors involved in the progression of cardiopathy. Clinical Science 104, 415-420.
8. Bustamante, J. M., Lo Presti, M. S., Rivarola, H.W., Fernández, J. E., Enders, J. E., Fretes, R., Palma, J. A. and Paglini-Oliva, P. A. (2007). Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. International Journal of Antimicrobial Agents 29, 733-739.
9. Cançado, J. R. (1999). Criteria of Chagas disease cure. Memórias do Instituto Oswaldo Cruz 94, 331-335.
10. Castro, J. (2006). Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Human and Experimental Toxicology 258, 471-479.
11. De Castro, S. L. (1993). The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Tropica 53, 83-98.
12. De Souza, W. (2002). From the cell biology to the development of new chemotherapeutic approaches against trypanosomatids: dreams and reality. Kinetoplastid Biology and Disease 1, 3.
13. Dias, J. C. P., Silveira, A. C. and Schofield, C. J. (2002). The impact of Chagas disease control in Latin America. Memórias do Instituto Oswaldo Cruz 97, 603-612.
14. Elias, F. E., Vigliano, C. A., Laguens, R. P., Levin, M. J. and Berek, C. (2003). Analysis of the presence of Trypanosoma cruzi in the heart tissue of three patients with chronic Chagas' heart disease. American Journal of Tropical Medicine and Hygiene 68, 242-247.
15. Fabro, D. E., Velazquez, N., Mendoza, M., Streiger, E., Arias, S., Denner, M., Del Barco, N., Amicone, C., Pravia, N., Malagrino, A. and Ruiz,M. (2007). Evaluación de ELISA F29 como marcador de eficacia del tratamiento etiológico en la enfermedad de Chagas. Parasitología Latinoamericana 62, 103-111.
16. Gobbi, P., Lo Presti, M. S., Baez, A., Fernández, A. R., Enders, J. E., Fretes, R., Gea, S., Paglini-Oliva, P. A. and Rivarola, H.W. (2010). Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi. Parasitology Research 107, 1279-1283.
17. Goijman, S. G. and Stoppani, A. O. M. (1985). Effects of nitroheterocyclic drugs on macromolecule synthesis and degradation in Trypanosoma cruzi. Biochemical Pharmacology 34, 1331-1336.
18. Gonzalez, N. S. and Cazzulo, J. J. (1989). Effects of trypanosomicidal drugs on proteins biosynthesis in vitro and in vivo by Trypanosoma cruzi. Biochemical Pharmacology 38, 2873-2878.
19. Gutierrez-Correa, J., Fairlamb, A. H. and Stoppani, A. O. (2001). Trypanosoma cruzi trypanothione reductase is inactivated by peroxidasegenerated phenothiazine cationic radicals. Free Radical Research 34, 363- 378.
20. Hamond, D. J., Cover, B. and Gutteridge,W. E. (1984). A novel series of chemical structures active in vitro against the trypomastigote form of Trypanosoma cruzi. Transactions of the Royal Society of Tropical Medicine and Hygiene 78, 91-95.
21. Higuchi, M., Benvenuti, L. A., Reis, M. M. and Metzger, M. (2003). Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovascular Research 60, 96-107.
22. Jiménez Arce, G., Villalobos Quesada, M. J., Jiménez Montero, E. and Palma Platero, W. (2007). Determinación de la efectividad de cinco protocolos de extracción de ADN a partir de material parafinado para estudios moleculares. Revista Médica Universitaria Costa Rica 1, 1-10.
23. Jones, D. C., Ariza, A., Chowb, W. A., Oza, L. S. and Fairlamb, A. H. (2010). Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Molecular and Biochemical Parasitology 169, 12-19.
24. Khan, M. and Omar, F. (2007). Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design. Drug Target Insights 2, 129-146.
25. Kirchhoff, F., Hofer, H.W. and Schachner, M. J. (1993). Myelinassociated glycoprotein is phosphorylated by protein kinase. Neuroscience 36, 368-381.
26. Krauth-Siegel, R. L. and Comini, M. A. (2008). Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochimica et Biophysica Acta 1780, 1236-1248.
27. Markvardsen, P., Bjerke, T., Rüdiger, N., Schiøtz, P. O., Gregersen, N., Justesen, J. and Paludan, K. (1995). A polymerase chain reaction-based method for the semiquantitative study of interleukin-8 mRNA in human basophil leukocytes. Scandinavian Journal of Clinical and Laboratory Investigation 55, 487-493.
28. Marr, J. J. and Docampo, R. (1986). Chemotherapy for Chagas' disease: a perspective of current therapy and considerations for future research. Reviews of Infectious Diseases 8, 884.
29. Miles, M. A., Toye, P. J., Oswald, S. C. and Godfrey, D. C. (1977). The identification by isoenzyme patterns of two distinct strain groups of Trypanosoma cruzi, circulating independently in a rural area of Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 71, 217-225.
30. Moncayo, A. (1999). Progreso en la interrupción de la transmisión de la Enfermedad de Chagas en los países del cono sur. MEDICINA (Buenos Aires) 59, 120-124.
31. Montes De Oca, M., Torres, S. H., Finol, H. J., Loyo, J. G., Vásquez, F. N., Hernández, N. and Anchústegui, B. (2007). Alteraciones musculares periféricas en la enfermedad de Chagas. Gaceta Médica de Caracas 115, 55-61.
32. Morello, A. (1988). The biochemistry of the mode of action of drugs and the detoxication mechanism in Trypanosoma cruzi. Comparative Physiology and Biochemistry 90, 1-12.
33. Moser, D. R., Kirchhoff, L. V. and Donelson, C. (1989). Detection of Trypanosoma cruzi by DNA amplification using polymerase chain reaction. Journal of Clinical Microbiology 27, 1477-1482.
34. Murta, S. M. F., Krieger, M. A., Montenegro, L. R., Campos, F. F., Probst, C. M., Ávila, A. R., Muto, N. H., De Oliveira, R. C., Nunes, L. R., Nirdé, P., Bruna-Romero, O., Goldenberg, S. and Romanha, A. J. (2006). Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Molecular and Biochemical Parasitology 146, 151-162.
35. Paglini-Oliva, P., Fernández, A. R. and Lacuara, J. L. (1987). Pharmacological and contractile response of myocardium of chagasic Albino Swiss mice. Acta Physiologica et Pharmacologica Latinoamericana 37, 395-401.
36. Paglini-Oliva, P. A. and Rivarola, H.W. (2003). Central nervous system agents used as Trypanosoma cruzi infection chemotherapy: phenothiazines and related compounds. Current Medicinal Chemistry - Anti-Infective Agents 2, 323-332.
37. Postan, M., Arnaiz, M. R. and Fichera, L. E. (1999). Respuesta de las células musculares cardíacas a la infección con Trypanosoma cruzi. Medicina (Buenos Aires) 59, 57-62.
38. Rivarola, H.W., Fernández, A. R., Enders, J. E., Fretes, R., Gea, S. and Paglini-Oliva, P. (2001). Effects of clomipramine on Trypanosoma cruzi infection in mice. Royal Society of Tropical Medicine and Hygiene 95, 1-5.
39. Rivarola, H.W. and Paglini-Oliva, P. A. (2002). Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Current Drug Targets - Cardiovascular and Hematological Disorders 2, 43-52.
40. Rivarola, H.W., Bustamante, J. M., Lo Presti, M. S., Fernández, A. R., Enders, J. E., Fretes, R. E., Gea, S. and Paglini- Oliva, P. A. (2005). Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Experimental Parasitology 111, 80-86.
41. Rodrígues Coura, J. and de Castro, S. (2002). A critical review on Chagas disease chemotherapy. Memórias do Instituto Oswaldo Cruz 97, 3-24.
42. Rossmanith, W. G., Hoffmeister, U., Wolfahrt, S., Kleine, B., McLean, M., Jacobs, R. A. and Grossman, A. B. (1999). Expression and functional analysis of endothelial nitric oxide synthase (eNOS) in human placenta. Molecular Human Reproduction 5, 487-494.
43. Roufogalis, B. D., Minocherhomjee, A. M. and Al-Jobore, A. (1983). Pharmacological antagonism of calmodulin. Canadian Journal of Biochemistry and Cell Biology 61, 927-933.
44. Sánchez Negrette, O., Sánchez Valdéz, F. J., Lacunza, C. D., GarcíaBustos, M. F., Mora, M. C., Uncos, A. D. and Basombrío, M. A. (2008). Serological evaluation of specific-antibody levels in patients treated for chronic. Clinical and Vaccine Immunology 15, 297-302.
45. Schmunis, G. A. (2007). Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Memórias do Instituto Oswaldo Cruz 102, 75-85.
46. Segura, M. A., Barberá, L. C., Ramos, F. and Basombrio, M. A. (1996). Regression of antibodies and resistance to reinfection in mice inoculated with an attenuated Trypanosoma cruzi strain and treated with nifurtimox. Memórias do Instituto Oswaldo Cruz 91, 316.
47. Sosa Estani, S. and Segura, E. L. (1999). Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Memórias do Instituto Oswaldo Cruz 94, 363-365.
48. Sosa-Estani, S., Viotti, R. and Segura, E. L. (2009). Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Memórias do Instituto Oswaldo Cruz 104, 167-180.
49. Suasnábar, D. F., Arias, E. and Streiger, M. (2000). Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic Chagasic patients. Revista Instituto Medicina Tropical São Paulo 42, 99-110.
50. Tarleton, R. L. (2001). Parasite persistence in the aetiology of Chagas disease. International Journal of Parasitology 31, 549-553.
51. Tovar, J., Cunningham, M. L., Smith, C., Croft, S. L. and Fairlamb, A. H. (1998). Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. Proceedings of the National Academy of Sciences USA 95, 5311-5316.
52. Urbina, J. A. (2002). Chemotherapy of Chagas disease. Current Pharmaceutical Design 8, 287-295.
53. Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M. and Cheeseman, I. (2008). A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of Sciences USA 105, 5022-5027.
54. World Health Organization (2010). WHO Report on Chagas Disease. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases.
55. Zhang, L. R. and Tarleton, L. (1999). Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. Journal of Infectious Diseases 180, 480-486.